Home > Publications Database > Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol. > print

001     257518
005     20231004134634.0
024 7 _ |a 10.14283/jpad.2023.11
|2 doi
024 7 _ |a pmid:36946458
|2 pmid
024 7 _ |a pmc:PMC9851094
|2 pmc
024 7 _ |a 2274-5807
|2 ISSN
024 7 _ |a 2426-0266
|2 ISSN
024 7 _ |a altmetric:144142110
|2 altmetric
037 _ _ |a DZNE-2023-00429
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a König, A.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Screening over Speech in Unselected Populations for Clinical Trials in AD (PROSPECT-AD): Study Design and Protocol.
260 _ _ |a Cham
|c 2023
|b Springer International Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1690535572_3221
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Speech impairments are an early feature of Alzheimer's disease (AD) and consequently, analysing speech performance is a promising new digital biomarker for AD screening. Future clinical AD trials on disease modifying drugs will require a shift to very early identification of individuals at risk of dementia. Hence, digital markers of language and speech may offer a method for screening of at-risk populations that are at the earliest stages of AD, eventually in combination with advanced machine learning. To this end, we developed a screening battery consisting of speech-based neurocognitive tests. The automated test performs a remote primary screening using a simple telephone.PROSPECT-AD aims to validate speech biomarkers for identification of individuals with early signs of AD and monitor their longitudinal course through access to well-phenotyped cohorts.PROSPECT-AD leverages ongoing cohorts such as EPAD (UK), DESCRIBE and DELCODE (Germany), and BioFINDER Primary Care (Sweden) and Beta-AARC (Spain) by adding a collection of speech data over the telephone to existing longitudinal follow-ups. Participants at risk of dementia are recruited from existing parent cohorts across Europe to form an AD 'probability-spectrum', i.e., individuals with a low risk to high risk of developing AD dementia. The characterization of cognition, biomarker and risk factor (genetic and environmental) status of each research participants over time combined with audio recordings of speech samples will provide a well-phenotyped population for comparing novel speech markers with current gold standard biomarkers and cognitive scores.N= 1000 participants aged 50 or older will be included in total, with a clinical dementia rating scale (CDR) score of 0 or 0.5. The study protocol is planned to run according to sites between 12 and 18 months.The speech protocol includes the following neurocognitive tests which will be administered remotely: Word List [Memory Function], Verbal Fluency [Executive Functions] and spontaneous free speech [Psychological and/ or behavioral symptoms]. Speech features on the linguistic and paralinguistic level will be extracted from the recordings and compared to data from CSF and blood biomarkers, neuroimaging, neuropsychological evaluations, genetic profiles, and family history. Primary candidate marker from speech will be a combination of most significant features in comparison to biomarkers as reference measure. Machine learning and computational techniques will be employed to identify the most significant speech biomarkers that could represent an early indicator of AD pathology. Furthermore, based on the analysis of speech performances, models will be trained to predict cognitive decline and disease progression across the AD continuum.The outcome of PROSPECT-AD may support AD drug development research as well as primary or tertiary prevention of dementia by providing a validated tool using a remote approach for identifying individuals at risk of dementia and monitoring individuals over time, either in a screening context or in clinical trials.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Dementia
|2 Other
650 _ 7 |a cognitive assessment
|2 Other
650 _ 7 |a machine learning
|2 Other
650 _ 7 |a phone-based
|2 Other
650 _ 7 |a screening
|2 Other
650 _ 7 |a speech biomarker
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: psychology
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Memory
|2 MeSH
650 _ 2 |a Speech
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
693 _ _ |0 EXP:(DE-2719)Prospect-AD-20220101
|5 EXP:(DE-2719)Prospect-AD-20220101
|e Population-based screening over speech for clinical trials in Alzheimer’s Disease
|x 1
693 _ _ |0 EXP:(DE-2719)DESCRIBE-20150101
|5 EXP:(DE-2719)DESCRIBE-20150101
|e A DZNE Clinical Registry Study of Neurodegenerative Diseases
|x 2
700 1 _ |a Linz, N.
|b 1
700 1 _ |a Baykara, E.
|b 2
700 1 _ |a Tröger, J.
|b 3
700 1 _ |a Ritchie, C.
|b 4
700 1 _ |a Saunders, S.
|b 5
700 1 _ |a Teipel, S.
|0 P:(DE-2719)2000026
|b 6
|u dzne
700 1 _ |a Köhler, S.
|0 P:(DE-2719)2811683
|b 7
|u dzne
700 1 _ |a Sánchez-Benavides, G.
|b 8
700 1 _ |a Grau-Rivera, O.
|b 9
700 1 _ |a Gispert, J. D.
|b 10
700 1 _ |a Palmqvist, S.
|b 11
700 1 _ |a Tideman, P.
|b 12
700 1 _ |a Hansson, O.
|b 13
773 _ _ |a 10.14283/jpad.2023.11
|g Vol. 10, no. 2
|0 PERI:(DE-600)2782183-3
|n 2
|p 314-321
|t The journal of prevention of Alzheimer's disease
|v 10
|y 2023
|x 2274-5807
856 4 _ |u https://pub.dzne.de/record/257518/files/DZNE-2023-00429_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/257518/files/DZNE-2023-00429_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:257518
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811683
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-23
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-23
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2023-08-23
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b JPAD-J PREV ALZHEIM : 2022
|d 2023-08-23
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21